| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_679e6ce6f86be1cc5508ec4a3132724e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2017-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dce0c07ce7f43eca0eb9a835af460fe2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05e33ebf7367a30bf0c7328b705fa532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7794a6327e067583165228d391f800c2 |
| publicationDate |
2019-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3546593-A1 |
| titleOfInvention |
Chemoendocrine score (ces) based on pam50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence |
| abstract |
The present invention refers to the development of a Chemo Endocrine Score (CES), based on the well-known PAM50 assay, for predicting whether a breast cancer patient is responsive to a chemotherapy or endocrine treatment, particularly in an HR+/HER2- breast patient beyond PAM50 Risk of Relapse (ROR) and intrinsic subtypes. Particularly, the clinical utility of this CES predictor lies in the PAM50 ROR-intermediate group, where the proportion of each CES group (endocrine-sensitive, intermediate and chemo-sensitive) is more than 25%. |
| priorityDate |
2016-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |